fxempire.com · 3 jul

CRISPR Therapeutics (CRSP) Price Forecast: Dual Breakout Targets Higher Prices

CRISPR Therapeutics confirmed a dual breakout from inverse head and shoulders patterns, strengthening the bullish outlook and pointing to additional upside if resistance continues to give way.

seekingalpha.com · 3 jul

Crispr Therapeutics: Casgevy's Pediatric Win A Trigger For Bullish Sentiment

Crispr Therapeutics secured FDA pediatric approval for Casgevy, expanding its addressable market and reinforcing its leadership in CRISPR/Cas9 gene editing. Casgevy's robust clinical efficacy, global approvals, and strong safety profile support its multibillion-dollar potential, despite initial slow commercial uptake due to complex treatment and high cost. CRSP's pipeline includes innovative in-vivo and allogeneic programs targeting cardiovascular and autoimmune diseases, aiming to further simplify and expand gene therapy applications.

fool.com · 3 jul

Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?

Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.

zacks.com · 30 jun

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

fool.com · 27 jun

CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

CRISPR Therapeutics AG continues to pioneer gene-editing through its landmark CASGEVY therapy while maintaining a robust cash position. Vertex Pharmaceuticals offers a profitable portfolio anchored by cystic fibrosis treatments alongside expansion into gene therapy and pain management.

zacks.com · 26 jun

CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors

CRISPR Therapeutics AG (CRSP) closed at $54.92 in the latest trading session, marking a +1.74% move from the prior day.

fool.com · 22 jun

The Best Stocks to Invest $1,000 in Right Now

Exploring some of the top bargains in a multi-trillion-dollar industry.

fool.com · 18 jun

Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year

The opportunity is enormous, but uncertainty remains.